Kintor Starts China Trials of Topical Androgen Receptor Inhibitor

Suzhou Kintor Pharma was approved to start China clinical trials of a proposed treatment for acne and androgenetic alopecia. GT20029, which degrades the androgen receptor protein via the E3 ubiquitin ligase pathway, is the first topical AR therapy to begin clinical tests, according to Kintor. In preclinical studies, the candidate was more effective than other small molecule AR inhibitors, while avoiding excessive drug accumulation and other side effects. More details.... Stock Symbol: (HK: 9939) Share this with colleagues: // //